Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Moodys
Baxter
McKinsey
Express Scripts

Last Updated: August 15, 2022

Investigational Drug Information for AGN-201904


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for AGN-201904?

AGN-201904 is an investigational drug.

There have been 58 clinical trials for AGN-201904. The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2014.

The most common disease conditions in clinical trials are Presbyopia, Ocular Hypertension, and Keratoconjunctivitis Sicca. The leading clinical trial sponsors are Allergan, Editas Medicine, Inc., and Vitae Pharmaceuticals Inc., an Allergan affiliate.

There are two US patents protecting this investigational drug and forty-three international patents.

Recent Clinical Trials for AGN-201904
TitleSponsorPhase
AGN-CognI.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer PatientsMilton S. Hershey Medical CenterPhase 1
A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar LinesAbbViePhase 1
Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic PresbyopiaAllerganPhase 2

See all AGN-201904 clinical trials

Clinical Trial Summary for AGN-201904

Top disease conditions for AGN-201904
Top clinical trial sponsors for AGN-201904

See all AGN-201904 clinical trials

US Patents for AGN-201904

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AGN-201904 See Plans and Pricing Prodrugs of proton pump inhibitors Winston Pharmaceuticals, Inc. (Newport Beach, CA) The United States of America as represented by the Department of Veteran Affairs (Washington, DC) N/A (Oakland, CA) The Reagents of the University of California (N/A) See Plans and Pricing
AGN-201904 See Plans and Pricing Process for preparing isomerically pure prodrugs of proton pump inhibitors Allergan, Inc. (Irvine, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AGN-201904

Drugname Country Document Number Estimated Expiration Related US Patent
AGN-201904 Argentina AR042513 2022-07-19 See Plans and Pricing
AGN-201904 Austria AT323695 2022-07-19 See Plans and Pricing
AGN-201904 Australia AU2003259154 2022-07-19 See Plans and Pricing
AGN-201904 Brazil BR0312802 2022-07-19 See Plans and Pricing
AGN-201904 Canada CA2492718 2022-07-19 See Plans and Pricing
AGN-201904 Colombia CO5690576 2022-07-19 See Plans and Pricing
AGN-201904 Germany DE60304726 2022-07-19 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Moodys
Baxter
McKinsey
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.